aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.
Company profile
Ticker
AUPH
Exchange
Website
CEO
Peter Greenleaf
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Aurinia Pharma U.S., Inc. • Aurinia Pharma Limited ...
AUPH stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
29 Feb 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
15 Feb 24
8-K
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2023 Net Revenue Results
5 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
2 Nov 23
8-K
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director
21 Sep 23
8-K
Dr. Daniel G. Billen appointed Chair of the Board of Directors
21 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
3 Aug 23
Transcripts
AUPH
Earnings call transcript
2023 Q4
15 Feb 24
AUPH
Earnings call transcript
2023 Q2
3 Aug 23
AUPH
Earnings call transcript
2023 Q1
4 May 23
AUPH
Earnings call transcript
2022 Q4
28 Feb 23
AUPH
Earnings call transcript
2022 Q3
3 Nov 22
AUPH
Earnings call transcript
2022 Q2
4 Aug 22
AUPH
Earnings call transcript
2022 Q1
10 May 22
AUPH
Earnings call transcript
2021 Q4
28 Feb 22
AUPH
Earnings call transcript
2021 Q3
3 Nov 21
AUPH
Earnings call transcript
2021 Q2
6 Aug 21
Latest ownership filings
SC 13D/A
ILJIN SNT Co., Ltd.
20 Mar 24
4
Peter Greenleaf
7 Mar 24
4
Joseph M Miller
7 Mar 24
4
Matthew Maxwell Donley
7 Mar 24
4
Scott Michael Habig
7 Mar 24
4
Stephen P. Robertson
7 Mar 24
4
Volker Knappertz
29 Feb 24
4
Volker Knappertz
22 Feb 24
4
Scott Michael Habig
22 Feb 24
4
Matthew Maxwell Donley
22 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 46.40 mm | 46.40 mm | 46.40 mm | 46.40 mm | 46.40 mm | 46.40 mm |
Cash burn (monthly) | 11.77 mm | 3.30 mm | 5.42 mm | 7.51 mm | 4.43 mm | 3.11 mm |
Cash used (since last report) | 80.44 mm | 22.58 mm | 37.05 mm | 51.32 mm | 30.25 mm | 21.26 mm |
Cash remaining | -34.04 mm | 23.81 mm | 9.35 mm | -4.93 mm | 16.15 mm | 25.14 mm |
Runway (months of cash) | -2.9 | 7.2 | 1.7 | -0.7 | 3.6 | 8.1 |
Institutional ownership, Q3 2023
38.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 197 |
Opened positions | 24 |
Closed positions | 24 |
Increased positions | 67 |
Reduced positions | 47 |
13F shares | Current |
---|---|
Total value | 384.06 bn |
Total shares | 56.29 mm |
Total puts | 1.10 mm |
Total calls | 1.97 mm |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 8.41 mm | $65.36 bn |
ILJIN SNT | 6.06 mm | $0.00 |
Armistice Capital | 6.05 mm | $46.99 bn |
NEA Management | 3.97 mm | $30.85 bn |
STT State Street | 2.60 mm | $20.20 bn |
Nuveen Asset Management | 2.35 mm | $18.28 bn |
Geode Capital Management | 1.49 mm | $11.56 bn |
Vanguard | 1.48 mm | $11.53 bn |
GS Goldman Sachs | 1.47 mm | $11.44 bn |
MS Morgan Stanley | 1.42 mm | $11.06 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Greenleaf Peter | Common Stock | Sell | Dispose S | No | No | 5.6 | 126,981 | 711.09 k | 1,522,114 |
6 Mar 24 | Miller Joseph M | Common Stock | Sell | Dispose S | No | No | 5.6 | 34,811 | 194.94 k | 495,928 |
6 Mar 24 | Matthew Maxwell Donley | Common Stock | Sell | Dispose S | No | No | 5.51 | 40,665 | 224.06 k | 584,072 |
6 Mar 24 | Scott Michael Habig | Common Stock | Sell | Dispose S | No | No | 5.6 | 17,777 | 99.55 k | 474,587 |
6 Mar 24 | Stephen P. Robertson | Common Stock | Sell | Dispose S | No | No | 5.6 | 57,745 | 323.37 k | 443,824 |
News
HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $13 Price Target
1 Mar 24
Cantor Fitzgerald Maintains Overweight on Aurinia Pharmaceuticals, Lowers Price Target to $10
23 Feb 24
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
22 Feb 24
HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Lowers Price Target to $13
22 Feb 24
RBC Capital Maintains Outperform on Aurinia Pharmaceuticals, Lowers Price Target to $8
16 Feb 24
Press releases
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
16 Apr 24
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
15 Apr 24
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
9 Apr 24
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
29 Feb 24
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
15 Feb 24